For: | Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, Lu MJ, Yang DL, Li X, Zhang ZH. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients. World J Gastroenterol 2015; 21(18): 5668-5676 [PMID: PMC4427693 DOI: 10.3748/wjg.v21.i18.5668] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i18/5668.htm |
Number | Citing Articles |
1 |
Yu-Qing Fang, Xiao-Yan Xu, Feng-Qin Hou, Wei Jia. A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients. Antiviral Therapy 2021; 26(6-8): 126 doi: 10.1177/13596535211059895
|
2 |
Yan Gu, Yao Zhang, Zhiyi Zhang, Jian Wang, Qing Zhang, Shaoqiu Zhang, Yilin Liu, Jiacheng Liu, Juan Xia, Xiaomin Yan, Jie Li, Xingxiang Liu, Rui Huang, Chao Wu. A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues. Annals of Hepatology 2024; 29(1): 101151 doi: 10.1016/j.aohep.2023.101151
|
3 |
Zequan Zhou, Suohui Zhang, Guozhong Yang, Yunhua Gao. Enhanced delivery efficiency and sustained release of biopharmaceuticals by complexation-based gel encapsulated coated microneedles: rhIFNα-1b example. Asian Journal of Pharmaceutical Sciences 2021; 16(5): 612 doi: 10.1016/j.ajps.2021.05.002
|
4 |
Xiang-an Zhao, Jian Wang, Jiacheng Liu, Guangmei Chen, Xiaomin Yan, Bei Jia, Yue Yang, Yong Liu, Da Gu, Zhaoping Zhang, Xiaoxing Xiang, Rui Huang, Chao Wu. Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment. Antiviral Research 2021; 193: 105146 doi: 10.1016/j.antiviral.2021.105146
|
5 |
Huilan Zhu, Changtai Wang, Yafei Zhang, Shaofeng Wei, Xu Li, Zhenhua Zhang. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa‐2a in chronic hepatitis B. Journal of Gastroenterology and Hepatology 2016; 31(12): 1963 doi: 10.1111/jgh.13414
|
6 |
Yafei Zhang, Wei Li, Zhongping Liu, Jun Ye, Guizhou Zou, Zhenhua Zhang, Jiabin Li. Combination therapy based on pegylated interferon alfa improves the therapeutic response of patients with chronic hepatitis B who exhibit high levels of hepatitis B e-antigen at 24 weeks. Medicine 2019; 98(36): e17022 doi: 10.1097/MD.0000000000017022
|
7 |
Ivana Lazarevic, Danijela Miljanovic, Ana Banko, Maja Cupic, Andja Cirkovic. Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis. Viruses 2024; 16(7): 1121 doi: 10.3390/v16071121
|
8 |
Mingfan Geng, Yuxin Li, Fangyuan Gao, Le Sun, Xue Yang, Rui Wang, Jialiang Chen, Qun Zhang, Gang Wan, Xianbo Wang. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice. International Journal of Infectious Diseases 2017; 62: 18 doi: 10.1016/j.ijid.2017.06.016
|
9 |
Hiroki Nishikawa, Hirayuki Enomoto, Yoshinori Iwata, Kyohei Kishino, Yoshihiro Shimono, Kunihiro Hasegawa, Chikage Nakano, Ryo Takata, Takashi Nishimura, Kazunori Yoh, Akiio Ishii, Nobuhiro Aizawa, Yoshiyuki Sakai, Naoto Ikeda, Tomoyuki Takashima, Hiroko Iijima, Shuhei Nishiguchi. Clinical implication of serum Wisteria floribunda agglutinin positive Mac‐2‐binding protein level on hepatitis B e‐antigen loss or seroconversion in hepatitis B e‐antigen positive patients. Hepatology Research 2016; 46(11): 1065 doi: 10.1111/hepr.12655
|